Merck & Co., Inc. stock (US58933Y1055): Q1 earnings beat with revenue growth

Merck & Co., Inc. reported stronger-than-expected Q1 2026 results on April 30, with EPS of -$1.28 beating estimates and revenue up 4.9% to $16.29 billion. The company guided FY revenue at $65.8-67.0 billion.

Merck & Co., Inc. released its first-quarter 2026 earnings on April 30, 2026, surpassing Wall Street expectations. The company posted an EPS of -$1.28, topping the consensus estimate of -$1.47 by $0.19, according to MarketBeat as of 05/08/2026. Quarterly revenue climbed 4.9% year-over-year to $16.29 billion, exceeding forecasts of $15.85 billion.

Merck issued full-year revenue guidance of $65.8 billion to $67.0 billion, bracketing the consensus estimate of $66.5 billion. This performance underscores the company's resilience in the pharmaceuticals sector amid ongoing innovation efforts. The stock closed at $111.26 on May 8, 2026, on the NYSE.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co., Inc.
• Sector/industry: Pharmaceuticals
• Headquarters/country: United States
• Core markets: Global, with strong US presence
• Key revenue drivers: Oncology, vaccines, animal health
• Home exchange/listing venue: NYSE (MRK)
• Trading currency: USD

Merck & Co., Inc.: core business model

Merck & Co., Inc. is a leading global healthcare company focused on discovering, developing, and delivering innovative medicines and vaccines. The firm operates in three main segments: human health pharmaceutical products, animal health, and other services. Key products include Keytruda, the world's top-selling cancer drug, alongside vaccines like Gardasil for HPV prevention. Merck invests heavily in R&D, with a pipeline targeting oncology, immunology, and infectious diseases, according to its investor relations site.

The company's business model emphasizes blockbuster drugs and strategic partnerships to drive growth. In the US, Merck holds significant market share in oncology, benefiting American investors through NYSE listing and exposure to domestic healthcare spending.

Main revenue and product drivers for Merck & Co., Inc.

Keytruda remains Merck's primary revenue engine, generating billions in sales from treating various cancers. Vaccines, particularly Gardasil, contribute substantially, with strong demand in the US market. Animal health products, including livestock and companion animal treatments, provide diversified income. Q1 2026 revenue growth of 4.9% to $16.29 billion reflects robust performance across these areas, as reported by MarketBeat as of 05/08/2026.

Trailing twelve-month EPS stood at $3.55 as of the latest data, with analysts projecting growth to $9.77 per share next year—a potential 89.34% increase. This outlook supports Merck's position as a growth-oriented pharma stock for US portfolios.

Industry trends and competitive position

The pharmaceutical industry faces patent cliffs, pricing pressures, and rising R&D costs, yet oncology and vaccines remain high-growth areas. Merck competes with Pfizer, Johnson & Johnson, and Roche, differentiating through Keytruda's dominance and a deep pipeline. Recent Q1 results highlight Merck's ability to outperform amid sector challenges.

Why Merck & Co., Inc. matters for US investors

Listed on the NYSE, Merck offers US investors direct access to a blue-chip pharma stock with substantial domestic revenue from Medicare and private payers. Its innovations address critical US health needs like cancer care, making it a staple in dividend-focused and growth portfolios.

Conclusion

Merck & Co., Inc. demonstrated solid Q1 2026 performance with earnings and revenue beats, alongside steady guidance. The company's strong product portfolio and pipeline position it well in pharmaceuticals. Investors track upcoming catalysts like pipeline updates and macroeconomic factors affecting healthcare.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.